Lutris Pharma

Tel Aviv-yafo, Israel

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.

$30.0M raised

Jan 2025

Venture - Series Unknown

Biotechnology First Aid Health Care Wellness

Top Investors

PontifaxColumbus Venture PartnersPeregrine VenturesaMoon FundCalifornia Institute for Regenerative Medicine

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Lutris Pharma

How much funding has Lutris Pharma raised?

Lutris Pharma has raised $30.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2025.

Who are Lutris Pharma's investors?

Lutris Pharma's investors include Pontifax, Columbus Venture Partners, Peregrine Ventures, aMoon Fund, California Institute for Regenerative Medicine.

Where is Lutris Pharma headquartered?

Lutris Pharma is headquartered in Tel Aviv-yafo, Israel.

What does Lutris Pharma do?

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.

What stage is Lutris Pharma at?

Lutris Pharma is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 28, 2025.

MLA

"Lutris Pharma — Funding & Investors." VCBacked, January 28, 2025, https://www.vcbacked.co/company/lutris-pharma. Accessed June 4, 2026.

APA

VCBacked. (2025). Lutris Pharma — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/lutris-pharma

Wikipedia (cite web)

{{cite web |title=Lutris Pharma — Funding & Investors |url=https://www.vcbacked.co/company/lutris-pharma |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 28, 2025.